Avidity Biosciences initiates Phase 3 study for Del-desiran in Myotonic Dystrophy Type 1
Avidity Biosciences has launched Phase 3 open-label extension study for Del-desiran, focusing on long-term safety and efficacy.
Therapeutic Area
Therapeutic area intelligence for Myotonic Dystrophy Type 1 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.